Aug 18, 2015 1:00pm EDT Tonix Pharmaceuticals Presents on the Development of TNX-102 SL for Post-Traumatic Stress Disorder (PTSD) at the 2015 Military Health System Research Symposium
Aug 10, 2015 7:00am EDT Tonix Pharmaceuticals Reports Second Quarter 2015 Financial Results and Provides Program Update
Jul 21, 2015 7:05am EDT Tonix Pharmaceuticals Appoints Mark T. Edgar, PhD as Senior Vice President of Product Development
Jun 22, 2015 8:00am EDT Tonix Pharmaceuticals Presents Non-clinical Data on TNX-201 at the 57th Annual Scientific Meeting of the American Headache Society
Jun 17, 2015 7:15am EDT Tonix Pharmaceuticals Announces Conditional Acceptance of Tonmya as Proposed Brand Name for Cyclobenzaprine HCl Sublingual Tablets, 2.8 mg
Jun 16, 2015 7:15am EDT Tonix Pharmaceuticals Initiates Phase 2 Clinical Study of TNX-201 in Episodic Tension-Type Headache
Jun 11, 2015 7:00am EDT Tonix Pharmaceuticals Presents Additional Data From Phase 2b BESTFIT Clinical Study at EULAR